Microbiome Therapeutics Market Size, Share & Industry | 2031

Segments - Microbiome Therapeutics Market by Types (Microbiome Drugs and Fecal Microbial Transplant), Applications (Diabetes, C. Difficile, Inflammatory Bowel Disease, Crohn’s Disease, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023-2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

Microbiome Therapeutics Market Outlook 2031

The global microbiome therapeutics market size was USD 94.86 Million in 2022 and is projected to reach USD 1.45 Billion by 2031 register a substantial CAGR 35.42% during the forecast period, 2023-2031. attributed to the rising incidence of diseases owing to microbiota dysbiosis in the gut. The market growth is further attributed to a large amount of funding made for the development studies of various biological drugs.

The microbe with genetic material including fungi, protozoa, bacteria, and viruses that lives inside the gut of a human body is known as the microbiome. They are mostly present in the large intestine. The bacteria present in the microbiome help in the regulation of the immune system, digestion of food, and protection against disease-causing bacteria.

The good health of a person is associated with the gut microbiome. When the number of microorganisms including actinobacteria, bacteroidetes, and firmicute alters, it leads to arthritis, diabetes, gastrointestinal disorders, lung & respiratory disorders, and several other neurological disorders. The reduction of these microorganisms is caused due to unhealthy lifestyles, long-term usage of antibiotics that are of heavy dosage, and increasing age.

Infectious diseases and organisms such as ulcerative colitis and clostridium difficile get induced in the human body due to a decrease in the level of beneficial microbiota.

The COVID-19 pandemic outbreak had a positive impact on the microbiome therapeutics market due to its association with immunity and various respiratory diseases. As per the reports published by the Human Microbiome Journal named “Lung microbiome and COVID-19: Possible Link and Implications,” lung microbiome is expected to have an impact on the seriousness and sensitivity of the pandemic. It is also expected to play a vital role in the prompting of the immune response against this widespread of SARS-CoV-2 infection.

Microbiome Therapeutics Market Trends, Drivers, Restraints, and Opportunities

Rise in prevalence of various diseases that are related to inactive lifestyle and growing number of the geriatric population are anticipated to fuel the market growth during the forecast period.
Availability of strong pipelines for drugs in the developed regions is expected to drive the market expansion in the coming years.
Increasing collaborations among several companies for the development and launch of drugs are key factors estimated to propel the market growth.
Rigid & strict regulations imposed by the government and lack of thorough research are key restraining factors that are expected to hinder the market growth.
Increasing initiatives taken by governments for raising funds in order to support research work presents a key factor projected to create profitable opportunities for the market expansion.

Scope of the Microbiome Therapeutics Market Report

The report on the global microbiome therapeutics market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Microbiome Therapeutics Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Types (Microbiome Drugs and Fecal Microbial Transplant) and Applications (Diabetes, C. Difficile, Inflammatory Bowel Disease, Crohn’s Disease, and Others)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	OpenBiome; Seres Therapeutics; Genome; Enterome Bioscience; Ritter Pharmaceuticals; Second MaaT Pharma; Rebiotix, Inc.; and MicroBiome Therapeutics LLC.

Microbiome Therapeutics Market Segment Insights

Microbiome drugs is expected to grow at a rapid pace

On the basis of types, the global microbiome therapeutics market is bifurcated into microbiome drugs and fecal microbial transplant. The fecal microbial transplant segment is projected to hold a key market share in the coming years owing to wide recommendation of the therapeutic method by professionals after it was approved by the Investigational New Drug (IND) for biological therapy.

The fecal microbial transplant dominated the market in 2019 as it was the only available option for C. difficile therapeutics. However, the microbiome drugs segment is expected to grow at a rapid pace owing to the presence of product pipelines in phase 2 that are strong and considered to be effective drugs.

Crohn’s disease is estimated to expand at a fast growth rate

Based on applications, the market is segmented into diabetes, C. difficile, inflammatory bowel disease, Crohn’s disease, and others. The C. difficile segment accounted for a large revenue share of the market in 2019 and is projected to exhibit a high CAGR during the forecast period owing to the wide approval of fecal microbial transplant, the only treatment available for it. However, Crohn’s disease is estimated to expand at a fast growth rate in the coming years due to the high presence of drug pipelines for its treatment.

Microbiome Therapeutics Market applications

Asia Pacific is anticipated to expand at a considerable CAGR

In terms of regions, the global microbiome therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in 2019 and is expected to grow substantially during the targeted period attributed to the availability of a large number of patients and presence of a large number of health conscious population.

Moreover, the presence of advanced research facilities and increasing expenditures for healthcare in the region present another key aspects for the regional market expansion. On the other hand, the market of Asia Pacific is anticipated to expand at a considerable CAGR during the forecast period owing to the increasing stability of the economy, increasing awareness regarding therapeutics among professionals, and rise in the number of initiatives by national institutes for biological research in the region.

Segments

The global microbiome therapeutics market has been segmented on the basis of

Types

Microbiome Drugs
Fecal Microbial Transplant

Applications

Diabetes
C. Difficile
Inflammatory Bowel Disease
Crohn’s Disease
Others

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

OpenBiome
Seres Therapeutics
Genome
Enterome Bioscience
Ritter Pharmaceuticals
Second MaaT Pharma
Rebiotix, Inc.
MicroBiome Therapeutics LLC

Competitive Landscape

Key players competing in the global microbiome therapeutics market are OpenBiome; Seres Therapeutics; Genome; Enterome Bioscience; Ritter Pharmaceuticals; Second MaaT Pharma; Rebiotix, Inc.; and MicroBiome Therapeutics LLC. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.

Some of the key players have received high funding for the development of pipelines for microbiome therapeutics. For example, nearly USD 160 million was invested by Seventure Partners for research in this field.

Microbiome Therapeutics Market key players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Microbiome Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Microbiome Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Microbiome Therapeutics Market - Supply Chain
  4.5. Global Microbiome Therapeutics Market Forecast
     4.5.1. Microbiome Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Microbiome Therapeutics Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Microbiome Therapeutics Market Absolute $ Opportunity
5. Global Microbiome Therapeutics Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Microbiome Therapeutics Market Size and Volume Forecast by Types
     5.3.1. Microbiome Drugs
     5.3.2. Fecal Microbial Transplant
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Microbiome Therapeutics Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Microbiome Therapeutics Market Size and Volume Forecast by Applications
     6.3.1. Diabetes
     6.3.2. C. Difficile
     6.3.3. Inflammatory Bowel Disease
     6.3.4. Crohn’s Disease
     6.3.5. Others
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Microbiome Therapeutics Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Microbiome Therapeutics Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Microbiome Therapeutics Demand Share Forecast, 2019-2026
8. North America Microbiome Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Microbiome Therapeutics Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Microbiome Therapeutics Market Size and Volume Forecast by Types
     8.4.1. Microbiome Drugs
     8.4.2. Fecal Microbial Transplant
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Microbiome Therapeutics Market Size and Volume Forecast by Applications
     8.7.1. Diabetes
     8.7.2. C. Difficile
     8.7.3. Inflammatory Bowel Disease
     8.7.4. Crohn’s Disease
     8.7.5. Others
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Microbiome Therapeutics Demand Share Forecast, 2019-2026
9. Latin America Microbiome Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Microbiome Therapeutics Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Microbiome Therapeutics Market Size and Volume Forecast by Types
     9.4.1. Microbiome Drugs
     9.4.2. Fecal Microbial Transplant
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Microbiome Therapeutics Market Size and Volume Forecast by Applications
     9.7.1. Diabetes
     9.7.2. C. Difficile
     9.7.3. Inflammatory Bowel Disease
     9.7.4. Crohn’s Disease
     9.7.5. Others
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Microbiome Therapeutics Demand Share Forecast, 2019-2026
10. Europe Microbiome Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Microbiome Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Microbiome Therapeutics Market Size and Volume Forecast by Types
     10.4.1. Microbiome Drugs
     10.4.2. Fecal Microbial Transplant
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Microbiome Therapeutics Market Size and Volume Forecast by Applications
     10.7.1. Diabetes
     10.7.2. C. Difficile
     10.7.3. Inflammatory Bowel Disease
     10.7.4. Crohn’s Disease
     10.7.5. Others
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Microbiome Therapeutics Demand Share Forecast, 2019-2026
11. Asia Pacific Microbiome Therapeutics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Microbiome Therapeutics Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Microbiome Therapeutics Market Size and Volume Forecast by Types
     11.4.1. Microbiome Drugs
     11.4.2. Fecal Microbial Transplant
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Microbiome Therapeutics Market Size and Volume Forecast by Applications
     11.7.1. Diabetes
     11.7.2. C. Difficile
     11.7.3. Inflammatory Bowel Disease
     11.7.4. Crohn’s Disease
     11.7.5. Others
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Microbiome Therapeutics Demand Share Forecast, 2019-2026
12. Middle East & Africa Microbiome Therapeutics Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Microbiome Therapeutics Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Microbiome Therapeutics Market Size and Volume Forecast by Types
     12.4.1. Microbiome Drugs
     12.4.2. Fecal Microbial Transplant
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Microbiome Therapeutics Market Size and Volume Forecast by Applications
     12.7.1. Diabetes
     12.7.2. C. Difficile
     12.7.3. Inflammatory Bowel Disease
     12.7.4. Crohn’s Disease
     12.7.5. Others
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Microbiome Therapeutics Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Microbiome Therapeutics Market: Market Share Analysis
  13.2. Microbiome Therapeutics Distributors and Customers
  13.3. Microbiome Therapeutics Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. OpenBiome
     13.4.2. Seres Therapeutics
     13.4.3. Genome
     13.4.4. Enterome Bioscience
     13.4.5. Ritter Pharmaceuticals
     13.4.6. Second MaaT Pharma
     13.4.7. Rebiotix, Inc.
     13.4.8. MicroBiome Therapeuti